Gout Management Guidelines

Acute Gout Attacks

Acute gout attacks typically last 7-10 days without treatment, but with appropriate treatment, acute attacks usually resolve more quickly, especially when treated within 24 hours of onset 1
Colchicine, NSAIDs, or corticosteroids effectively reduce pain and inflammation in acute gout attacks, with combination therapy (e.g., colchicine + NSAIDs or colchicine + corticosteroids) suitable for severe or polyarticular attacks 1, 2
The American College of Rheumatology recommends first-line therapies, including NSAIDs, low-dose colchicine, and glucocorticoids, for acute gout attacks 3

Untreated or inadequately treated gout can progress to a chronic inflammatory condition, potentially leading to chronic tophaceous gouty arthropathy with persistent synovitis 1, 2

Prophylaxis is essential when starting ULT to prevent prolonged or recurrent attacks, and should be continued for at least 6 months, with options including low-dose colchicine, NSAIDs, or low-dose prednisone (<10 mg/day) 1, 2
Prophylaxis reduces flare risk by at least 50% 2
ULT should be continued without interruption during acute attacks 1
The target serum urate level is below 6 mg/dL, although for patients with tophi or frequent flares, a target of <5 mg/dL may be suggested 4
For patients with persistently high serum uric acid concentrations (>6 mg/dL) despite maximum-tolerated XOI dose and continued frequent gout flares (>2 flares/year), switching to a second XOI over adding a uricosuric agent is conditionally recommended 3

Prophylaxis should be continued for at least 3 months after achieving target serum urate in patients without tophi, and for at least 6 months in patients with tophi 1
Prophylactic therapy with low-dose colchicine or NSAIDs reduces the risk for acute gout attacks in patients initiating ULT, and should be continued for more than 8 weeks 5
Discontinuing anti-inflammatory prophylaxis after only 8 weeks approximately doubles the rate of acute gout flares 5

For patients with frequent flares (≥2/year) or nonresolving tophi despite maximal conventional therapy, consider switching to pegloticase, as strongly recommended for those who have failed XOI treatment, uricosurics, and other interventions 3
Recurrent gout flares despite low serum uric acid levels can occur due to ongoing dissolution of monosodium urate crystal deposits in joints and tissues, triggering inflammatory responses even when serum levels appear controlled 6